**EXHIBIT
      31.1**





CERTIFICATION
      PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES


EXCHANGE
      ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF


THE
      SARBANES-OXLEY ACT OF 2002





I,
      Henry
      Fong, certify that:





1.
      I have
      reviewed this Quarterly Report on Form 10-QSB of Inhibiton Therapeutics, Inc.
      (the "registrant);





2.
      Based
      on my knowledge, this report does not contain any untrue statement of a material
      fact or omit to state a material fact necessary to make the statements made,
      in
      light of the circumstances under which such statements were made, not misleading
      with respect to the period covered by this report;





3.
      Based
      on my knowledge, the financial statements, and other financial information
      included in this report, fairly present in all material respects the financial
      condition, results of operations and cash flows of the registrant as of, and
      for, the periods presented in this report;





4.
      I am
      responsible for establishing and maintaining disclosure controls and procedures
      (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant
      and have:





(a)
      Designed
      such disclosure controls and procedures, or caused such disclosure controls
      and
      procedures to be designed under my supervision, to ensure that material
      information relating to the registrant, including its consolidated subsidiaries,
      is made known to me by others within those entities, particularly during the
      period in which this report is being prepared;





(b)
      [Paragraph omitted in accordance with SEC transition instructions contained
      in
      SEC Release 34-47986];





(c)
      Evaluated
      the effectiveness of the registrant's disclosure controls and procedures and
      presented in this report my conclusion about the effectiveness of the disclosure
      controls and procedures, as of the end of the period covered by this report
      based on such evaluation; and





(d)
      Disclosed
      in this report any change in the registrant's internal control over financial
      reporting that occurred during the registrant's most recent fiscal quarter
      that
      has materially affected, or is reasonably likely to materially affect, the
      registrant's internal control over financial reporting; and





5.
      I have
      disclosed, based on my most recent evaluation of internal control over financial
      reporting, to the registrant's auditors and the audit committee of the
      registrant's board of directors (or persons performing the equivalent
      functions):





(a)
      All
      significant deficiencies and material weaknesses in the design or operation
      of
      internal control over financial reporting which are reasonably likely to
      adversely affect the registrant's ability to record, process, summarize and
      report financial information; and





(b)
      Any
      fraud, whether or not material, that involves management or other employees
      who
      have a significant role in the registrant's internal control over financial
      reporting.





Date:
                December 13, 2005
            /s/
                Henry FongHenry
                FongPresident,
                Chief Executive Officer andChief
                Financial Officer